Mersana Therapeutics(MRSN) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results - Dose escalation advancing in Phase 1 clinical trials of both XMT-1660 and XMT-2056 - Continue to expect to announce initial XMT-1660 clinical data and initiate expansion in the second half of 2024 - Capital resources expected to support current operating plan commitments into 2026 - Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., August 13, 2024 – Mersana Therapeutics, Inc. (NASDAQ: MRSN) ...